Literature DB >> 10735828

Evidence based medicine.

T Eden1.   

Abstract

Mesh:

Year:  2000        PMID: 10735828      PMCID: PMC1718285          DOI: 10.1136/adc.82.4.275

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


× No keyword cloud information.
  24 in total

1.  Clinical trials, consensus conferences, and clinical practice.

Authors:  A D Sniderman
Journal:  Lancet       Date:  1999-07-24       Impact factor: 79.321

2.  Research questions for systematic reviews must be unambiguous from protocol stage.

Authors:  G Eysenbach
Journal:  BMJ       Date:  1999-11-06

3.  Patterns of care and survival for children with acute lymphoblastic leukaemia diagnosed between 1980 and 1994.

Authors:  C A Stiller; E M Eatock
Journal:  Arch Dis Child       Date:  1999-09       Impact factor: 3.791

4.  Suspended judgment. Memories of the British Streptomycin Trial in Tuberculosis. The first randomized clinical trial.

Authors:  A B Hill
Journal:  Control Clin Trials       Date:  1990-04

5.  Results of Medical Research Council Childhood Leukaemia Trial UKALL VIII (report to the Medical Research Council on behalf of the Working Party on Leukaemia in Childhood).

Authors:  O B Eden; J S Lilleyman; S Richards; M P Shaw; J Peto
Journal:  Br J Haematol       Date:  1991-06       Impact factor: 6.998

6.  Paediatric oncology and intensive care treatments: changing trends.

Authors:  I N Keengwe; F Stansfield; O B Eden; N D Nelhans; O R Dearlove; A Sharples
Journal:  Arch Dis Child       Date:  1999-06       Impact factor: 3.791

7.  Accumulation of high levels of methotrexate polyglutamates in lymphoblasts from children with hyperdiploid (greater than 50 chromosomes) B-lineage acute lymphoblastic leukemia: a Pediatric Oncology Group study.

Authors:  V M Whitehead; M J Vuchich; S J Lauer; D Mahoney; A J Carroll; J J Shuster; D W Esseltine; C Payment; A T Look; J Akabutu
Journal:  Blood       Date:  1992-09-01       Impact factor: 22.113

8.  Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM 86.

Authors:  A Reiter; M Schrappe; W D Ludwig; W Hiddemann; S Sauter; G Henze; M Zimmermann; F Lampert; W Havers; D Niethammer
Journal:  Blood       Date:  1994-11-01       Impact factor: 22.113

9.  High survival rate in advanced-stage B-cell lymphomas and leukemias without CNS involvement with a short intensive polychemotherapy: results from the French Pediatric Oncology Society of a randomized trial of 216 children.

Authors:  C Patte; T Philip; C Rodary; J M Zucker; H Behrendt; J C Gentet; J P Lamagnère; J Otten; D Dufillot; F Pein
Journal:  J Clin Oncol       Date:  1991-01       Impact factor: 44.544

10.  Minimal residual disease in childhood acute lymphoblastic leukemia: analysis of patients in continuous complete remission or with consecutive relapse.

Authors:  A Biondi; S Yokota; T E Hansen-Hagge; V Rossi; G Giudici; O Maglia; G Basso; C Tell; G Masera; C R Bartram
Journal:  Leukemia       Date:  1992-04       Impact factor: 11.528

View more
  1 in total

1.  Pediatric nephrologists' beliefs regarding randomized controlled trials.

Authors:  Aaron G Wightman; Assaf P Oron; Jordan M Symons; Joseph T Flynn
Journal:  J Investig Med       Date:  2014-01       Impact factor: 2.895

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.